lapatinib has been researched along with metformin in 11 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (metformin) | Trials (metformin) | Recent Studies (post-2010) (metformin) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 17,793 | 3,176 | 12,526 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 9 (81.82) | 24.3611 |
2020's | 1 (9.09) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
del Barco, S; Martín-Castillo, B; Menéndez, JA; Oliveras-Ferraros, C; Vázquez-Martín, A | 1 |
Komurov, K; Moss, TJ; Muller, M; Nagrath, D; Ram, PT; Seviour, EG; Tseng, JT; Yang, L | 1 |
Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z | 1 |
Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
Agbor-Tarh, D; Andersson, M; Azim, HA; Bradbury, I; Cufer, T; de Azambuja, E; Di Cosimo, S; Fumagalli, D; Gralow, J; Harris, L; Keane, M; Kroep, J; Moreno-Aspitia, A; Piccart-Gebhart, M; Salman, P; Sarp, S; Simon, SD; Sonnenblick, A; Toi, M; Wolff, AC | 1 |
Chen, X; Chen, Y; He, S; Jin, C; Lin, Z; Zhang, Y; Zhou, X; Zhu, S | 1 |
2 review(s) available for lapatinib and metformin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Metformin; Models, Biological; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2009 |
1 trial(s) available for lapatinib and metformin
Article | Year |
---|---|
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Insulin; Lapatinib; Metformin; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
8 other study(ies) available for lapatinib and metformin
Article | Year |
---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Genomics; Glucose; Humans; Hypoglycemic Agents; Lapatinib; Macrolides; Metformin; Models, Biological; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
Metformin alleviates ethanol-induced cardiomyocyte injury by activating AKT/Nrf2 signaling in an ErbB2-dependent manner.
Topics: Apoptosis; Cell Line; Ethanol; Lapatinib; Metformin; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2023 |